Tacrine

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

Biochem/physiol Actions Tasimelteon is a Dual Melatonin Receptor Agonist (DMRA) recently approved (Hetlioz) for the treatment of Non-24-hour sleep–wake disorder, a disorder primarily found in the totally blind, where a lack of normal

Biochem/physiol Actions Tasimelteon is a Dual Melatonin Receptor Agonist (DMRA) recently approved (Hetlioz) for the treatment of Non-24-hour sleep–wake disorder, a disorder primarily found in the totally blind, where a lack of normal

Tasimelteon is a melatonin MT1 and MT2 receptor agonist.

Application Refer to the product&#8242s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

A trace amine that activates TAAR1 (EC₅₀s = 0.08, 0.

A trace amine that activates TAAR1 (EC₅₀s = 0.08, 0.